行业解读：可能拖累外包项目的五个原料假设

On the loading dock, a drum of raw material can look like the least interesting object in pharmaceutical development. Its contents may cost less than the meeting devoted to discussing them. Yet, an impurity hitchhiking inside, or a subtle change in the powder’s physical properties, can give that drum considerable influence over your program.

Drug sponsors will often go to great lengths to scrutinize their CDMO partnerships. But often they forget that the ingredients those partners purchase deserve attention, too. A capable manufacturer still needs to understand what it’s being asked to work with, and if sponsors automatically assume that communication has been clear, they could find themselves staring at the raw material drum with great contempt. 

Having the right raw-material strategy and supplier-CDMO partnership in place well before anyone attempts to manufacture even one nanogram of product could be the difference between a successful end product and one that ends up in the dumpster out back. Both are critical to sponsors and CDMOs alike, and both warrant in-depth discussion. That's why the agenda at the upcoming CDMO Live Americas conference, Oct. 20-21 in Boston, is loaded with this very topic.

In that vein, I'd suggest that sponsors preparing their next manufacturing campaign review the following five assumptions about raw materials that could severely disrupt their progress.

Assumption #1: The Specification Tells Us Everything We Need To Know

A specification answers the questions its authors thought to ask, but your process may have additional questions.

The international Q8 guidance on pharmaceutical development calls for understanding material attributes that influence manufacturing and product performance. For excipients, that includes characteristics relevant to their function and compatibility. Passing an identity test

For instance, let’s consider nitrite impurities in excipients. FDA has described how these impurities can contribute to nitrosamine formation in certain drug products, and mitigation options include evaluating nitrite levels across suppliers and lots. An excipient's role in the formulation may be familiar, but a reactive fellow traveler deserves its own investigation.

Ask your development team which properties actually matter. Does moisture affect stability? Could particle size influence dissolution? What evidence connects the limits on the specification to acceptable performance in your process?

This doesn’t justify testing everything detectable. Work with the CDMO to identify consequential attributes and the evidence needed to control them. Review which material lots supported development and how much variability those experiments explored. If every successful run used the same lot, you’ve learned something about that lot. Broader confidence still needs support.

The sponsor should fund that understanding before an investigation makes the spending unavoidable.

Assumption #2: Another Supplier Can Provide The Same Thing

A chemical name can conceal a surprisingly busy neighborhood.

In a 2021 study of iron raw materials used in cell culture, researchers traced changes in cell growth, protein production, and glycosylation to manganese impurities rather than iron. The finding that manganese could improve productivity while altering glycosylation is an instructive complication for anyone who equates a bigger harvest with an unchanged product.

The cells responded to the whole chemical mixture, including its uninvited guests.

In practice, that means sponsors need to treat a proposed supplier substitution as a scientific question. Ask what differs in the manufacturing route, impurity profile, or physical characteristics, and which of those differences matter for your application. Agree on the studies needed to demonstrate suitability before approving the switch.

Apply the same curiosity to a backup source. Establish what qualification work remains, how long it will take, and who funds it. Procurement's discovery of another seller starts the conversation, but the sponsor's technical team needs evidence before that seller becomes a usable alternative.

Assumption #3: Clinical Supply Proves Commercial Availability

A supplier’s willingness to send a small development order says little about its ability to support your launch. The math changes with batch size, manufacturing frequency, and the quantity lost along the way.

An FDA discussion of drug shortages identified delays in receiving raw materials and components as one significant cause of production delays. Sponsors should therefore test supply assumptions while there’s still time to change them.

Build a demand forecast with the CDMO that includes development work and qualification batches, along with realistic allowances for losses and replacement material. Then ask the supplier to confirm the relevant grade, manufacturing site, and quantities it can support. Discuss minimum orders and what happens if your forecast changes.

Confirm who actually manufactures the material. Two distributors can lead back to the same plant, so counting vendors won’t necessarily tell you how many supply options you have.

Examine the cost of being cautious. A reserve of extra inventory can help prevent delays if it's stored properly and used before it expires. Otherwise, organizations with less capital, such as small biotechs, risk wasting money they could put to better use elsewhere.

The reserve should reflect a credible disruption scenario.

Assumption #4: The CDMO Owns The Material Risk

Having someone else place the order can create a wonderfully soothing distance from the problem. Resist it.

The FDA’s quality agreement guidance recommends specifying which party establishes component specifications, qualifies and monitors suppliers, and performs required sampling and testing. It also addresses responsibilities for reporting and approving changes. Neither party can use the agreement to delegate away its regulatory responsibilities.

For the sponsor, the practical task is to make those responsibilities work on, let’s say, an ordinary Tuesday. Name the person who evaluates a supplier change and the person authorized to approve the resulting technical work. Establish how notices travel from the material manufacturer through the CDMO to your team.

Decide which changes require advance review and what information that review needs. A notice that arrives after the replacement material has entered production offers limited opportunity for thoughtful intervention.

The sponsor also needs to answer promptly. A conscientious CDMO can flag a problem and still be stranded while its customer decides who should respond.

Assumption #5: Once It Arrives, It’s Ready To Use

A delivery truck pulling into the receiving dock is a satisfying sight. However, it doesn’t establish that the material is available for manufacturing.

The international Q7 questions and answers on materials management, which address active ingredient manufacturing, describe incoming examination before materials enter a facility under quarantine. Receipt and readiness are separate milestones.

Ask your CDMO to show when material is expected to be released for use. The schedule should account for sampling, the applicable tests, review of the results, and resolution of any discrepancies. Check whether an outside laboratory adds another queue. Confirm that required documentation will arrive with the shipment.

Then work backward from the manufacturing slot. Agree on when a delay triggers escalation and what recovery options remain. Expedited freight can shorten a journey; it won’t finish an investigation into an unexpected result. Sponsors need visibility into the entire interval before promising a batch date to their clinical colleagues.

Before The Drum Becomes The Problem

When a batch is waiting on a raw material, the problem may trace back to an assumption made much earlier. That’s why these questions belong in development planning and CDMO selection, while there’s still time to investigate and act on the answers.

For sponsors, the next step is to review the evidence with the CDMO, identify the unanswered questions that could affect the program, and agree on who will resolve them. Give that work time and funding, then revisit the decisions as the process changes and demand grows.

The drum on the loading dock may never look especially interesting, but it deserves your attention long before it becomes the reason production stops.